Force Oncology offers the CounterforceⓇ System, a wearable Tumor Treating Fields platform that delivers calibrated oscillating electric fields to disrupt cell division in glioblastoma and metastatic non‑small cell lung cancer. The device is designed for continuous, comfortable use and can be combined with standard systemic therapies, aiming to improve patient adherence and extend survival outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with aggressive cancers such as glioblastoma and metastatic non‑small cell lung cancer have limited treatment options, and existing Tumor Treating Fields (TTFields) devices are often uncomfortable, leading many eligible patients to decline therapy despite demonstrated survival benefits.
Solution
Force Oncology is developing the CounterforceⓇ System, a next‑generation TTFields platform that delivers oscillating electric fields to disrupt cancer cell division. The system aims to improve clinical efficacy while enhancing patient comfort and usability compared with current TTFields products. By iterating on device design, the company seeks to provide a wearable solution that can be used continuously, maximizing the therapeutic exposure needed for survival extension. The technology is intended to complement standard systemic therapies and be applicable in both brain tumor and metastatic lung cancer settings, delivering a survival benefit comparable to that of new pharmaceuticals.
Target Audience
Primary customers are oncology centers and clinicians treating patients with newly diagnosed or recurrent glioblastoma and metastatic non‑small cell lung cancer who are candidates for TTFields therapy.
Features
- Wearable generator and electrode array designed for around‑the‑clock use with improved ergonomics
- Oscillating electric field delivery calibrated to interfere with mitosis in glioblastoma and NSCLC cells
- Patented design enhancements aimed at reducing patient burden and increasing adherence
- Compatibility with standard systemic treatments to enable combined therapeutic regimens
- Planned integration of data collection for clinical monitoring and outcome tracking